---
created: 2025-04-13
updated: 2025-04-13T10:53
id: Cf|60?cpWv
specialty: pharmaco
specialty_id: 560
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::02-immunology::04-immunosuppressants::04-therapeutic-antibodies::ipilimumab
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::05-immune-checkpoint-interactions
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::05-immune-checkpoint-interactions::ipilimumab
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::miscellaneous-pharm::akadds
  - source/ak-step1-v11::$ankingadds::fa2020::pathology
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield"
type: flashcard
---

# Question
Ipilimumab is a checkpoint inhibitor that binds to **CTLA-4** on T cells

---

# Answer
